Sunrest Lifescience Ltd Stock Price Today (NSE: SUNREST)

Sunrest Lifescience Ltd

35.00+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Sunrest Lifescience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sunrest Lifescience Ltd share price today is 35.00, up +0.00% on NSE/BSE as of 22 June 2026. Sunrest Lifescience Ltd (SUNREST) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 18.45 (Cr). The 52-week high for SUNREST share price is 60.70 and the 52-week low is 32.10. At a P/E ratio of 10.42x, SUNREST is currently trading below its industry average P/E of 31.77x.

Sunrest Lifescience Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
41.00
Low
35.00
Volume
3.7K
Change
-1.55%

Sunrest Lifescience Ltd share price chart: -1.55% return over the past month. 52-week high ₹60.70, 52-week low ₹32.10.

Sunrest Lifescience Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
36.0036.0035.0035.004.80K (Cr)
35.0035.0035.0035.001.60K (Cr)
36.0036.0035.0035.009.60K (Cr)
38.0038.0038.0038.001.60K (Cr)
39.6041.0039.6040.304.80K (Cr)
35.5035.5035.5035.501.60K (Cr)
37.4037.4036.3036.303.20K (Cr)
36.6536.6535.5535.553.20K (Cr)
37.0037.5037.0037.504.80K (Cr)
36.5037.0036.5037.003.20K (Cr)

Sunrest Lifescience Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
36.0036.0035.0035.00-2.78%
35.5041.0035.0035.00-1.41%
37.0037.5035.5536.30-1.89%
44.6047.6535.2037.00-17.04%
34.6043.9033.5043.80+26.59%
45.0045.0032.1033.00-26.67%
42.2043.0041.5541.55-1.54%
46.5050.0043.0043.00-7.53%
47.2047.2040.1542.00-11.02%
49.2049.2044.0047.20-4.07%
53.8557.8049.0549.20-8.64%
52.0060.7050.2551.10-1.73%

AI Research Briefing

Powered by Gemini · 2026-04-09

Micro-cap pharma play hinging on a successful rights issue, but liquidity risk and promoter selling make it a dangerous bet.

Research Confidence
5.0/10Moderate
MICRO-CAP DARK HORSEBreakdown: 1M: -12.24% | 3M: -12.6% | 6M: -14.09%Cheap relative to industry P/E, but justified given micro-cap status and risks.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Sunrest Lifescience is undertaking a rights issue to raise Cr, offering 4.29 million shares at each, including a premium. The issue opened on April 2, 2026, and closes on April 30, 2026. The rights entitlement ratio is 1:1.

CORE STORY (THE REAL GAME)

Sunrest is a micro-cap pharma company attempting to scale via rights issue. This is a capital raise, not a turnaround, and the market will likely punish any operational misses.

Why Now
  • Rights issue open until April 30, 2026
  • Indian pharma sector projected to reach $130 billion by 2030
  • Recent board meetings indicate focus on fund raising
Potential Catalysts
  • Successful closure of rights issue
  • Significant order wins or partnerships
  • Positive regulatory changes in the pharma sector
Key Risks
  • Micro/SME cap = liquidity risk
  • Promoter holding decreased by 16.41%
  • Negative cash flow from operations in recent fiscals
Institutional Activity

Promoter selling suggests lack of confidence.

Macro Context

Indian pharma industry is growing, but faces global pricing pressures.

Cash Flow Quality

No Free Cash Flow reported

3–6 Month Outlook

Next 3-6 months depend on successful deployment of rights issue proceeds. Failure to improve financials will lead to further downside.

Primary Thesis Risk

Failure of rights issue or inability to effectively deploy capital.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Return on Capital (ROCE)

N/A

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Sunrest Lifescience Ltd Valuation Check

Excellent

Price to Earnings (P/E)

10.42x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

53.50%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-41.38%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

120.99%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.94x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

9.45x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sunrest Lifescience Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SUNREST across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Attractive Valuation (P/E: 10.42 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (120.99%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Strong Interest Coverage (9.45x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (53.50%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Profit Decline Concern (-41.38%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Sunrest Lifescience Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Sunrest Lifescience Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
5.9/100
35
₹18.45
10.4
Average
0.9
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Sunrest Lifescience Ltd PE Ratio History

Historical price-to-earnings ratio for SUNREST — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.68₹51.5075.7x
FY 20234.76₹63.4513.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Sunrest Lifescience Ltd Quarterly Performance

Latest quarterly metrics for SUNREST — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

120.99%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-41.38%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Sunrest Lifescience Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SUNREST — calculated from daily price history

47RSI 14
Neutral — RSI 47

Momentum is balanced — neither overbought nor oversold.

SMA 50
40
▼ Price below SMA 50 — Short-term bearish
SMA 200
49
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
8K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Sunrest Lifescience Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Sunrest Lifescience Ltd (SUNREST) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Sunrest Lifescience Ltd

About SUNREST (Sunrest Lifescience Ltd)

Sunrest Lifescience Ltd (SUNREST) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a... current market capitalisation of ₹18.45 (Cr). The debt-to-equity ratio stands at 0.94, reflecting the company's capital structure. Investors tracking SUNREST share price can monitor key metrics including P/E ratio, promoter holding of 53.50%, and quarterly earnings growth.

Company Details

Symbol:SUNREST
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

SUNREST Share Price: Frequently Asked Questions

What is the current share price of Sunrest Lifescience Ltd?

Sunrest Lifescience Ltd (SUNREST) trades at ₹35.00 on NSE. Market cap ₹18.45 (Cr). Educational data only.

What is the P/E ratio of Sunrest Lifescience Ltd?

Sunrest Lifescience Ltd has a P/E of 10.42x vs industry average 31.77x.

What is the Bull Run score for Sunrest Lifescience Ltd?

Sunrest Lifescience Ltd has a Bull Run score of 5.9/100 based on 25+ financial parameters.

Does Sunrest Lifescience Ltd pay dividends?

Sunrest Lifescience Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Sunrest Lifescience Ltd?

Sunrest Lifescience Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Sunrest Lifescience Ltd?

Sunrest Lifescience Ltd has debt-to-equity of 0.94.

Is Sunrest Lifescience Ltd a good investment?

Bull Run gives Sunrest Lifescience Ltd a score of 5.9/100. This is not investment advice — consult a SEBI-registered advisor.